Chemotherapy
Prognostic Factors and Survival in Pericardial Mesothelioma: A Systematic Review and Quantitative Analysis
Cancers 2026 August 11 [Link] Michał Kapałka, Estera Pazek, Michał Krawiec, Michał Sikorski, Grzegorz Hirnle, Tomasz Hrapkowicz Abstract Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO…
Read MoreIdentification of disulfidptosis-related molecular subtypes in pleural mesothelioma demonstrates a correlation with the immune infiltration, prognosis and therapy efficacy
Discover Oncology 2026 July 25 [Link] Jing Ding, Xuefeng Huang, Wenxiu Yao, Tongyu Lin Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive malignancy with increasing incidence, high mortality, and limited treatment options. Disulfidptosis, a newly identified form of regulated cell death, may play an important role in cancer, but its relevance in PM…
Read MoreLow baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma
Lung Cancer 2026 September [Link] Antoine Torchiat, Karina Silina, Arya Ashok Nair, Laura Viktoria Heeb, Isabelle Opitz, Anurag Gupta, Alessandra Curioni-Fontecedro Abstract Introduction: The cyclic GMP-AMP synthase (cGAS)/STING pathway, a central DNA-sensing mechanism, is known to activate anti-tumor immune response but may also promote tumor progression when chronically activated. Given the role of asbestos-induced chronic…
Read MoreEfficacy of Perioperative Platinum-Pemetrexed Chemotherapy Combined With Pleurectomy/Decortication for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July 25 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Kyoshiro Takegahara, Takashi Kijima, Seiki Hasegawa, Soichiro Funaki Abstract Background: The optimal timing of chemotherapy in multimodal treatment of pleural mesothelioma remains unclear. This study evaluated the efficacy of adjuvant chemotherapy (AC) after neoadjuvant chemotherapy (NAC)…
Read MoreEpiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma
Lung Cancer 2026 September [Link] Roberta Noberini, Ioanna Bischinioti, Simone Zanetti, Alessandro Vai, Giulia Sedda, Eltjona Mane, Claudia Bardoni, Giulia Robusti, Marianna D’Ercole, Rosanna Mancari, Ugo Cavallaro, Nicoletta Colombo, Luca Bertolaccini, Mariano Lombardi, Nicola Fusco, Lorenzo Spaggiari, Domenico Galetta, Tiziana Bonaldi Abstract Pleural mesothelioma (PM) is an aggressive tumor that arises from mesothelial cells as…
Read MoreTreatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication
Annals of Surgical Oncology 2026 October [Link] Ryo Wakejima, Hironori Ishibashi, Ayaka Asakawa, Yuya Ishikawa, Yusuke Sugita, Kenichi Okubo Abstract Background: We evaluate recurrence patterns and assess the efficacy of local treatment for oligo-recurrence in patients with diffuse pleural mesothelioma (PM) following extended pleurectomy/decortication (P/D) with multimodal therapy. Methods: This retrospective study included 69 patients…
Read MoreMaintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
Scientific Reports 2026 July 15 [Link] Okan Aydin, Zehra Sucuoglu Isleyen, Mert Erciyestepe, Ahmet Emin Ozturk, Sermin Dinc Sonusen, Tugay Atasever, Simay Cokgezer, Ebru Cicek, Ayse Gul Satman Durmaz, Lamia Seker Can, Gozde Balkaya Aykut, Tuba Baydas, Miray Aydogan, Seval Ay Ersoy, Muhammed Mustafa Atci, Kayhan Erturk Abstract Malignant pleural mesothelioma (MPM) is an aggressive…
Read MoreNavigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Cancers 2026 June 30 [Link] Giorgio D’Annibale, Francesco Santullo, Lorenzo Barberis, Claudio Lodoli, Tommaso Partipilo, Giusi Giulia La Manna, Antonia Strippoli, Alexia Spring, Fabio Pacelli, Carlo Abatini Abstract Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing…
Read MoreMulticystic peritoneal mesothelioma mimicking recurrent pseudomyxoma peritonei
Journal of Surgical Case Reports 2026 July 7 [Link] Alessia Scarton, Marco Tonello, Elisa Pizzolato, Carola Cenzi, Ivana Cataldo, Vasileios Mourmouras, Pierluigi Pilati, Antonio Sommariva Abstract Multicystic peritoneal mesothelioma (MCPM) is a borderline variant of peritoneal mesothelioma with indolent behaviour but a significant recurrence rate without radical treatment. Due to its rarity, risk factors and…
Read MoreLong-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report
Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition, combination immune checkpoint inhibitors are frequently limited by immune-related adverse events. A 72-year-old man with epithelioid MPM underwent extrapleural pneumonectomy followed by adjuvant chemotherapy with…
Read More
Skip to content